MedTrace Logo

Understanding the Immune System's Role in Tree Nut and Peanut Allergies: Key Biomarkers for Diagnosis and Treatment Monitoring and Treatment Targets

NCT06554691 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2025-12-02

No results posted yet for this study

Summary

Peanut and tree nuts belong to the main elicitors of pediatric food allergy and are the main cause of near fatal reactions in children requiring emergency management. Oral immunotherapy has emerged as an alternative treatment option for the management of food allergies, to enhance patients' safety and quality of life. Monitoring if the therapy is working relies on oral food challenges during the course of treatment. There is a clear need for reliable biomarkers that are reflective of the clinical progression during oral food challenges and during immunotherapy that would help with patient stratification and possibly for personalized treatment approaches in the future

The aim of this study is to measure immune parameters in the blood of nut-allergic participants during oral food challenges and during the course of oral immunotherapy.

The main questions the study aims to answer are:

1. Identify immune markers that correlate with clinical reactivity
2. Identify immune changes and markers that correlate with immunotherapy outcome

Researchers will compare these immune parameters between nut-allergic participants on oral immunotherapy and with nut-allergic participants on avoidance diet. Additionally, we will also compare the immune parameters of these nut-allergic participants with those healthy adults.

Conditions

  • Food Allergy
  • Food Allergy in Children
  • Food Allergy Peanut
  • Tree Nut Allergies
  • Allergy;Food
  • Oral Immunotherapy for Food Allergy

Sponsors & Collaborators

  • Centre Hospitalier du Luxembourg

    collaborator OTHER

  • Luxembourg Institute of Health

    lead OTHER_GOV

Principal Investigators

  • Annette Kuehn · Luxembourg Institute of Health

Eligibility

Min Age
2 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-02
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Luxembourg

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06554691 on ClinicalTrials.gov